Development and Evaluation of Nanoparticles Based Topical Gel Containing Antifungal Drug Fluconazole
Main Article Content
Abstract
The objective of this work was to prepare Fluconazole nanoparticles, and then incorporated into the freshly prepared gel for transdermal delivery, reducing the oral side effects of the drug and forenhancing stability. Fluconazole is commonly used antifungal agents for the treatment of local and systemic fungal infections. In this study Fluconazole nanoparticles was prepared by using Eudragit RL 100 by nanoprecipitation method with different drugs to polymer (1:1, 1:2 and 1:3) and stabilizer (Poloxamer 188) ratios (0.5%, 0.75% and 1%) and evaluated for various parameters. Drug-excipients compatibility was performed by FTIR study. The particle size, polydispersity index, Zeta potential, % Entrapment efficiency and % drug content of all the formulations were found in the range of 16.8 to 48.9nm, 0.229 to 0.558, -11.6 to -26.6 mv, 28.41% to 95.78% and 59% to 97.38%. From SEM studies it was revealed that Fluconazole nanoparticles particles are spherical in shape and without any agglomeration. From the in-vitro drug release study, it was revealed that sustained release of same formulation last up to 12 hours. From the stability study, it was revealed that the F5 formulation was stable at 40°C ± 2°C /75% ± 5%RH and 4°C. The optimised formulation F5 was selected to prepare Fluconazole loaded nanoparticles based topical gels using different concentration of Carbopol 934 and 940 and characterized for pH, spreadability, drug content, viscosity and in-vitro drug diffusion. Among the five formulations, G5 was selected as the best formulation. The pH of all formulations was found near to the skin pH value. The in-vitrodiffusion study of Fluconazole gel (G5) showed 94.75%. The optimized formulation G5 was checked for mechanism and kinetics of drug release. It is found it following Zero order release and non-Fickian mechanism. The selected Gel formulation G5 was found to be stable at 40°C ± 2°C /75% ± 5%RH and 4°C, it is clear that the formulation did not undergo any chemical changes found more stable at room temperature
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Basha BN, Prakasam K, Goli D & College BMR. Formulation and evaluation of Gel containing Fluconazole-Antifungal Agent. IJDDR. 2010;3(4), 109–128.
II. Kalpana SP, Mikolaj M, Courtney LS, Nicole KB, Priyanka G, Audra LS. Challenges and
opportunities in dermal/transdermal delivery. 2010; 1(1): 109–31.
III. Gungor S, Erdal MS &Aksu B. New formulation strategies in topical antifungal therapy. Journal of Cosmetics, Dermatological Sciences and Applications. 2013;3(1), 56–65.
IV. Ravikumar ATRP. Polymeric nanoparticles based topical drug delivery. Asian Journal of Biomedical and Pharmaceutical Sciences. 2015; 47(5), 5–12.
V. http://www.pharmainfo.net/reviews/transdermal-drug-delivery-system-review.
VI. Abdul RA. Fluconazole for the treatment of cutaneous leishmaniasis caused by leishmania. N Eng. J Med. 2002; 346(12):211-3.
VII. Shelke SJ, Shinkar D M &Saudagar RB. Topical gel: a novel approach for development of topical drug delivery system. CODEN: IJPTFI. 2013;5(3), 2739–63.
VIII. Chandel AB, Parashar NG, Kumar A, Sharma V. An overview on gel formulation. Int. J. Pharmacy rev. Res.2013; Vol1:18-22.
IX. Saroha K, Singh S, Aggarwal A, Nanda S. Transdermal Gels- An alternative vehicle for drug delivery. Int.J. Pharm. Chem. Biol. Sci. 2013; 3(3), pp495-503.
X. Indora N, Kaushikm D. Design, development and evaluation of ethosomal gel of fluconazole for topical fungal infection. Int J EngSci Invent Res Dev. 2015; I(Viii):280.
XI. Guinea J, Sanchez-Somolinos M, Cuevas O, Pelaez, T, Bouz, E. Fluconazole resistance mechanisms in Candida krusei: the contribution of efflux-pumps. Med Mycol. 2006 Sep; 44(6):575-8.
XII. Bartrakova EV, Kabanov AV. “Pluronic block copolymers. Evolution of drug delivery concept frominert nanocarriers to biological response modifier”. J. Controle Release. 2008; 130. (2):98-106.
XIII. Briede RH. Application of Carbomer water gel 1%. Pharm Week. 1983; 118(9): 170-4.
XIV. Kurakula M, Srinivas C, Kasturi N, Diwan P V. Formulation and Evaluation of Prednisolone
Proliposomal Gel for Effective Topical Pharmacotherapy. 2012;4(1):35–43.
XV. Biswal B, Karna N, Nayak J, Joshi V. Formulation and Evaluation of Microemulsion Based TopicalHydrogel Containing Lornoxicam. 2014;4(12):77–84.
XVI. Namasivayam SKR, Kumar P, Bharani RSA, Nishanth AN, Nivedh SK. Cyclodextrin nanoparticles
incorporated fluconazole and medicinal plant extracts preparation for the improved anti-fungalactivity against human pathogenic fungi. 2014;6(6):1756–61.
XVII. Nair R, Vishnu K, Kumar KSA, Badivaddin T, Sevukarajan M. Formulation and Evaluation of SolidLipid Nanoparticles of Water-SolubleDrug Isoniazid. 2011;3(5):1256–64.
XVIII. Kumar GD, Razdan BK, Meenakshi B, Chandanwari PO. Research Article Formulation AndEvaluation of Nanoparticles Containing Artemisinin HCL. 2014;3(2):925–34.
XIX. Prachi B. Shekhawat. Preparation and evaluation of clotrimazole nanostructured lipid carrier fortopical delivery. Int J Pharma Bio Sci. 2013;4(1):407–16.
XX. Samein LH. Preparation and evaluation of nystatin loaded-solid-lipid nanoparticles. 2014; 6:2–7.
XXI. A PA, D CP. Development and evaluation of nanogel as a carrier for transdermal delivery of
Aceclofenac. 2012;2(4):125–32.
XXII. Parashar B, Kabra A, Chandel A. Formulation and evaluation of gel containing miconazole nitrate anantifungal agent. 2013;2(June):18–28.
XXIII. Indora N, Kaushik D. Design, development and evaluation of ethosomal gel of fluconazole for
topical fungal infection. Int J EngSci Invent Res Dev. 2015; I(Viii):280.
XXIV. Ping L, Ya-Ni D, Jun-Ping Z, Ai-Qin W, Qin W. Chitosan– alginate nanoparticles as a novel drugdelivery system for nifedipine. International Journal of Biomedical Science. 2008; 4:3: 221 -8.
XXV. Lakshmi PK, Kumar MK, Sridharan A, Bhaskaran S. A c a d e m i c S c i e n c e s Formulation andevaluation of ibuprofen topical gel: a novel approach for penetration enhancement. 2011;3(3).
XXVI. Napoleon R, N NNS, Venkateshwara K, Vinoth J. Preparation and characterization of nisoldipine
nanoparticles by nanoprecipitation method. 2012;4(11):1989–94.
XXVII. Kumar S, Parchuri DB, Kumar GSS, Goli D, Karki R. Formulation and evaluation of nanoparticulate
drug delivery system of acyclovir for. World J Pharm Sci. 2013;2(6):5602–17.
XXVIII. Sumer PDER.“Formulation and evaluation of nano particles of an anti-viral drug” by Dissertationsubmitted to the Rajiv Gandhi University of Health Sciences, Karnataka, Bangalore master ofpharmacy in pharmaceutics 2015;(April).
XXIX. Das S, Samanta A, Bose A. Design, development and evaluation of fluconazole topical gel. Asian JPharm Clin Res. 2015;8(2):6–9.
XXX. Ashwini A M, Sarode S, Patil P, Patil A. Formulation and evaluation of nevirapine loadednanoparticles. Int J Pharm Rev Res. 2015;5